Skip to main content

Table 4 Summary of base case results for pioglitazone versus placebo

From: Cost-effectiveness of pioglitazone in type 2 diabetes patients with a history of macrovascular disease: a German perspective

Outcome (all reported values are discounted)

Pioglitazone

Placebo

Difference (PIO – PLA)

Clinical outcomes

   

Life expectancy (years)

10.044 (0.140)

9.871 (0.139)

0.172

Quality-adjusted life expectancy (QALYs)

7.543 (0.102)

7.422 (0.102)

0.120

Cost outcomes

   

Total direct costs (€)

105,433 (2,650)

103,834 (2,618)

1,599

Incremental cost-effectiveness based on life expectancy

€9,281 per life year gained

  

Incremental cost-effectiveness based on quality-adjusted life expectancy

€13,294 per QALY gained

  
  1. Values shown are means with standard deviation in parentheses; PIO = pioglitazone; PLA = placebo; QALY = quality-adjusted life-years. Incremental values are given as the pioglitazone value minus the placebo value.